Scarica l'app Stockscreener
43.04
1.97%
0.83
Dopo l'orario di chiusura:
44.80
1.76
+4.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GPCR Giù?
Forum
Previsione
Precedente Chiudi:
$42.21
Aprire:
$42.15
Volume 24 ore:
806.22K
Relative Volume:
0.85
Capitalizzazione di mercato:
$3.06B
Reddito:
-
Utile/perdita netta:
$-141.43M
Rapporto P/E:
-17.51
EPS:
-2.4581
Flusso di cassa netto:
$-226.41M
1 W Prestazione:
-5.05%
1M Prestazione:
-19.52%
6M Prestazione:
+26.55%
1 anno Prestazione:
+58.88%
Intervallo 1D:
$41.82
$43.71
Intervallo di 1 settimana:
$40.68
$47.32
Portata 52W:
$15.80
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Nome
Structure Therapeutics Inc Adr
Settore
Industria
Telefono
(650) 457-1978
Indirizzo
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
43.04 | 3.00B | 0 | -141.43M | -226.41M | -2.4581 |
VRTX
Vertex Pharmaceuticals Inc
|
429.85 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
709.21 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.09 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.93 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.14 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | Canaccord Genuity | Buy |
| 2026-03-26 | Iniziato | Wolfe Research | Peer Perform |
| 2025-05-02 | Iniziato | Citigroup | Buy |
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2025-01-08 | Iniziato | Stifel | Buy |
| 2024-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-21 | Iniziato | JP Morgan | Overweight |
| 2024-04-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-07-27 | Iniziato | Piper Sandler | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2023-02-28 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-28 | Iniziato | Guggenheim | Buy |
| 2023-02-28 | Iniziato | Jefferies | Buy |
| 2023-02-28 | Iniziato | SVB Securities | Outperform |
Mostra tutto
Structure Therapeutics Inc Adr Borsa (GPCR) Ultime notizie
Structure Therapeutics (GPCR) Is Down 7.2% After Strong Phase 2 Oral GLP‑1 Obesity Data – Has The Bull Case Changed? - Sahm
Avoiding Lag: Real-Time Signals in (GPCR) Movement - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpShould You Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Why Structure Therapeutics Shares Are Suddenly Sinking - TipRanks
Structure Therapeutics (GPCR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
Structure Therapeutics Reports Weight Loss Success in Obesity Drug Trial - HarianBasis.co
Universal Beteiligungs und Servicegesellschaft mbH Buys 67,338 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Upgraded by Canaccord Genuity Group to Strong-Buy Rating - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Structure Therapeutics (GPCR) Leerink Global Healthcare Conference 2025 Summary - Quartr
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions - The Manila Times
Five obesity and diabetes studies from Structure Therapeutics head to ADA - Stock Titan
Assessing Structure Therapeutics (GPCR) Valuation After Recent Share Price Pullback - Sahm
Peregrine Capital Management LLC Buys Shares of 84,324 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
[Form 4] Structure Therapeutics Inc. Insider Trading Activity - Stock Titan
[ARS] Structure Therapeutics Inc. SEC Filing - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) details 2026 virtual shareholder meeting - Stock Titan
Structure Therapeutics (GPCR) COO & GC Matthew Lang files initial Form 3 - Stock Titan
Structure Therapeutics (GPCR) Proxy filing Summary - Quartr
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
Discipline and Rules-Based Execution in GPCR Response - Stock Traders Daily
Is Structure Therapeutics (GPCR) Building a Legal-Led Edge in Its Obesity and Metabolic Pipeline Strategy? - Sahm
Structure Therapeutics (NASDAQ:GPCR) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
FMR LLC funds trim 17,452 Structure Therapeutics (GPCR) ADS holdings - Stock Titan
LLY Stock Down as FDA Asks for More Safety Data on Oral Obesity Pill - TradingView
How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q1 Results? - TradingView
Structure Therapeutics Appoints Matthew Lang as COO and General Counsel to Advance Obesity Drug Pipeline - Minichart
Structure Therapeutics stock rating maintained at Outperform by Leerink - Investing.com
Structure Therapeutics Appoints Matthew Lang as Chief Operating Officer - TipRanks
Structure Therapeutics (NASDAQ: GPCR) appoints Matthew Lang as COO and General Counsel - Stock Titan
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel - The Manila Times
Structure Therapeutics names Matthew Lang as COO and counsel - Investing.com
Metsera legal chief joins Structure as COO ahead of Phase 3 - Stock Titan
Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval? - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
SG Americas Securities LLC Cuts Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Behavioral Patterns of GPCR and Institutional Flows - Stock Traders Daily
Why Structure Therapeutics Stock Is Suddenly Sinking - TipRanks
Why Structure Therapeutics Shares Are Sliding Today - TipRanks
Aberdeen Group plc Sells 322,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Why Structure Therapeutics Stock Suddenly Took Off Today - TipRanks
Capricorn Fund Managers Ltd Invests $17.57 Million in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Why Structure Therapeutics Stock Is Suddenly Surging - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 10.8%What's Next? - MarketBeat
LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill? - TradingView — Track All Markets
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Forte Biosciences (FBRX) - The Globe and Mail
Exchange Traded Concepts LLC Sells 32,241 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc Adr Azioni (GPCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):